Hasone (six mg, 10 days) Chronic inflammatory disease Respiratory disease Kidney insufficiency Metastatic
Hasone (six mg, ten days) Chronic inflammatory disease Respiratory illness Kidney insufficiency Metastatic neoplasm Diabetes Arterial hypertension Coronary heart disease Angiotensin-1 receptor antagonist Angiotensin converting enzyme inhibitor Hospitalized Sufferers (n = 10) 56.5 (543) 10 (100) 23.8 (225.9) 0 (0) 0 (0) 0 (0) 6 (27) 1 (10) two (20) four (40) 3 (30) 1 (10) 1 (10) 1 (ten) 4 (40) two (20) 1 (10) two (10) Convalescent Patients (n = 24) 56 (558) 22 (91.six) 26.1 (22.88.1) 0 (0) 0 (0) 0 (0) 88 (7035) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Handle Collective (n = 13) 54 (517) four (31) 22.3 (20.25.7) 0 (0) 0 (0) 0 (0) Betamethasone disodium Protocol p-Value 0.08 0.046 0.161 1 1 1 0.001 0.151 0.021 0.001 0.003 0.151 0.151 0.151 0.001 0.021 0.151 0.Patient (Z)-Semaxanib Inhibitor CharacteristicsSARS CoV-2 therapyPre-existing conditionsMedicationViruses 2021, 13, x FOR PEER REVIEWViruses 2021, 13,4 of4 ofTable 2. Cohort characteristics: differences have been calculated by Kruskal allis test; IQR, interquartile range; LDH, lactate dehydrogenase; CRP, C-reactive protein. Table 2. Cohort traits: differences have been calculated by Kruskal allis test; IQR, interquartile range; LDH, lactate Hospitalized Padehydrogenase; CRP, C-reactive protein. Convalescent Healthy Contients p-Value Patients (n = 24) trols (n = 14) Hospitalized Sufferers Convalescent Individuals Healthy Controls (n = ten) p-Value (n = ten) (n = 24) (n = 14) Syndecan-1 (ng/mL), median (IQR) 142 (85.281.3) 71.2 (40.141.5) 31.6 (17.14.7) 0.Syndecan-1 (ng/mL), median (IQR) 142 (85.281.3) Lymphocytes (rel., ), median (IQR) Lymphocytes (rel., ), median (IQR) 22.2(16.53.two) Creatinine (mg/dL), median (IQR) Creatinine (mg/dL), median (IQR) 0.95 (0.88.3) Bilirubin (mg/dL), median (IQR) Bilirubin (mg/dL), median (IQR) 0.4 (0.three.7) AST (U/L), median (IQR) AST (U/L), median (IQR) 36 (262) Gamma-GT (U/L), median (IQR) Gamma-GT (U/L), median (IQR) 82 (4046) LDH (U/L), median (IQR) LDH (U/L), median (IQR) 279 (23285) CRP (mg/dL), median (IQR) CRP (mg/dL), median (IQR) two.5 (0.five) Albumin (g/dL), median (IQR) Albumin (g/dL), (two.7.9) (IQR) 3.four median Ferritin ( /L), median (IQR) Ferritin ( /L), (22006) 383 median (IQR) Interleukin-6 (pg/mL), median (IQR) 14.5 (83) Interleukin-6 (pg/mL), median (IQR) 71.two (40.141.5) 28.5 (27.24.4) 31.6 (17.14.7) n.d. 0.0010.23 22.2(16.53.2) 28.5 (27.24.four) n.d. 1 (0.8.two) 0.23 0.77 0.95 (0.88.three) 0.9 (0.81.0) 0.9 (0.81.0) 1 (0.eight.two) (0.2.7) 0.77 0.43 0.4 (0.three.7) 0.five (0.four.0) 0.5 0.five (0.four.0) 0.five (0.2.7) 0.43 36 (262) 28 (254) 29 (225) 0.63 28 (254) 29 (225) 0.63 82 (4046) 27 (226) 22 (124) 0.003 27 (226) 22 (124) 0.003 279 (23285) 61 (574) 149 61 (574) 149 (12779) (12779) 0.001 0.001 two.five (0.5) 0.five (0.five.5) 0.5 0.5 (0.five.5) 0.5 (0.5.five) (0.5.5) 0.001 0.001 4.4 (4.3.five) 4.9 (four.1.three) (four.1.3) 0.001 0.001 three.four (2.7.9) four.four (four.3.5) four.9 252 (8998) 87 (4278) (4278) 0.0020.002 383 (22006) 252 (8998) 87 two (two) 2 (2) 2 (2) 0.001 14.5 (83) 2 (two) 0.three.2. Considerably Improved Syndecan-1 Levels in Convalescent COVID-19 Individuals 3.2. Drastically Increased Syndecan-1 Levels in Convalescent COVID-19 Patients Convalescent COVID-19 patients (blood drawn at aamedian of 88 days following symptom Convalescent COVID-19 individuals (blood drawn at median of 88 days just after symptom onset) after aamild disease course showed considerably elevated SDC-1 levels in comparison to onset) just after mild disease course showed substantially elevated SDC-1 levels compared the the healthier control population 0.
